PRMT5 overexpression has been reported in many malignancies, including glioblastoma [118], melanoma [119], ovary [120], lung [121], breast [122], stomach [123], and lymphoma [124], which correlates with its ability to directly methylate several transcription factors (Table 2). Here, PRMT5 is linked to lymphoma.